NanoCellect Biomedical Announces New Distribution Partnerships in Asia and Europe

 NanoCellect Biomedical, the leading provider of microfluidic flow cytometry platforms, has announced new distributor partnerships in Asia and Europe to expand its global reach and provide greater accessibility to its innovative technologies. Shanghai BioHandler Life Technology Co., Ltd. and T&T Wisdom Bio-tech. Co., Ltd. will distribute NanoCellect’s products in North and South China respectively, while partnering with Medikonia Ltd. to better serve scientists in Hong Kong and Macau. In Europe, Paralab Bio will be responsible for distribution in Spain and Portugal. Swift Analytical Ltd, a distributor of laboratory equipment and supplies based in England, will distribute NanoCellect’s products in the United Kingdom and Ireland.

“The addition of these new distributor partners in Asia and Europe is a significant milestone for NanoCellect,” said Chris Neary, CEO of NanoCellect. “We are thrilled to partner with these highly respected companies to expand our global reach and bring our technology to researchers around the world.”

NanoCellect’s microfluidic flow cytometry platform is used by researchers to analyze and sort cells for various life science research applications, such as gene & cell therapies, single-cell genomics, antibody discovery or sample enrichment. With its innovative technology, the platform has become a valuable tool for both academic and industry researchers worldwide.

Dr. Paul DiGregorio, VP Commercial at NanoCellect, commented, “NanoCellect’s technology platform is a game-changer in the field of life science research, and we are confident that our customers will benefit greatly from its use.”

NanoCellect’s new distributor partners will be responsible for sales and marketing efforts in their respective regions, with support from NanoCellect’s dedicated sales and technical support team. The company’s innovative technologies and commitment to advancing research make it an attractive partner for distributors looking to offer cutting-edge solutions to their customers.

With these new partnerships in place, NanoCellect is poised for continued growth and success as it expands its global presence and continues to provide valuable solutions to researchers globally.

To learn more about NanoCellect Biomedical’s global distributors and partnerships, click here or email info@nanocellect.com.

About NanoCellect Biomedical
NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring the high cell viability required to advance cell-based research. We develop and deliver microfluidic-based solutions that are affordable, compact, and easy to use. Our expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

For more information, please visit www.nanocellect.com and follow us on LinkedIn, Facebook, and Twitter.

NanoCellect Biomedical
Olivier Déry
877-745-7678
nanocellect.com

ContactContact

Categories

  • Biotechnology
  • Business
  • Medical & Health
  • Medical Research
  • Pharmaceuticals
  • Science
  • Scientific Research
  • Technology

NanoCellect Biomedical Awarded $1.8M Federal Grant to Advance Imaging Flow Cytometry with Artificial Intelligence Technologies

 NanoCellect Biomedical Inc., a leader in the development and manufacture of microfluidic cell sorting solutions for cell-based assays, today announced it has received a $1.8 million Phase II Small Business Innovation Research (SBIR) grant through the National Institutes of Health’s National Institute of General Medical Sciences to continue its development of imaging flow cytometry technology to sort cells based on features derived from artificial intelligence. This grant extends NanoCellect’s successful research programs to develop novel imaging flow cytometry technology, expanding on an ongoing, multi-year research collaboration between the University of California, San Diego (UCSD) and NanoCellect to advance the single-cell analysis technologies.

“A critical limitation in the selection of cells for the production of biologic in the biopharma industry is the time it takes to confirm that a given cell is in fact the best at producing protein and proliferating,” said Will Alaynick, PhD, a NanoCellect co-founder. “Building upon our sterile and gentle WOLF platform, we apply our image-based sorting technology to select ideal cells as early as possible.” This award from the NIH represents an important peer-reviewed validation of our science and our ability to commercialize this technology for wide adoption in bioprocessing and other diverse applications.”

About NanoCellect Biomedical

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research. We develop and deliver microfluidic based solutions that are affordable, compact, and easy-to-use. Our expanding portfolio of instruments and consumables enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

For more information, please visit www.nanocellect.com and follow us on LinkedIn, Facebook, and Twitter.

NanoCellect Biomedical

Olivier Dery

877-745-7678

nanocellect.com

ContactContact

Categories

  • Artificial Intelligence
  • Biotechnology
  • Business
  • Medical & Health
  • Medical Research
  • Pharmaceuticals
  • Science
  • Technology